On May 30, 2024, Novo Integrated Sciences, Inc. announced the receipt of a Ready, Willing and Able (RWA) confirmation from HSBC for a Standby Letter of Credit (SBLC) as part of its monetizing program. The company is projected to receive approximately $78 million in gross funding proceeds from the SBLC by June 14, 2024. These funds are intended to finalize the acquisition of the Ophir Collection, granting Novo Integrated Sciences sole ownership. The company's CEO, Robert Mattacchione, emphasized the significance of this non-dilutive financing strategy in supporting the company's growth and global objectives, particularly for micro-cap companies facing funding challenges. Novo Integrated Sciences focuses on a holistic approach to healthcare, integrating medical technology, advanced therapeutics, and rehabilitative science to decentralize non-catastrophic healthcare delivery.

On May 30, 2024, Novo Integrated Sciences, Inc. announced the receipt of a Ready, Willing and Able (RWA) confirmation from HSBC for a Standby Letter of Credit (SBLC) as part of its monetizing program. The company is projected to receive approximately $78 million in gross funding proceeds from the SBLC by June 14, 2024. These funds are intended to finalize the acquisition of the Ophir Collection, granting Novo Integrated Sciences sole ownership. The company's CEO, Robert Mattacchione, emphasized the significance of this non-dilutive financing strategy in supporting the company's growth and global objectives, particularly for micro-cap companies facing funding challenges. Novo Integrated Sciences focuses on a holistic approach to healthcare, integrating medical technology, advanced therapeutics, and rehabilitative science to decentralize non-catastrophic healthcare delivery.